Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Qiagen ( (QGEN) ) has shared an announcement.
QIAGEN N.V. announced a managerial transaction involving Mr. Roland Sackers, a member of the managing body, who sold shares worth approximately $2.46 million on August 13, 2025, at the NYSE. This transaction may have implications for the company’s stock performance and investor perception, as it reflects internal financial decisions by key management personnel.
The most recent analyst rating on (QGEN) stock is a Hold with a $42.50 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
QIAGEN N.V. is a company operating in the biotechnology industry, primarily focusing on providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company is listed on multiple stock exchanges, including the NYSE and various European markets.
Average Trading Volume: 1,463,714
Technical Sentiment Signal: Buy
Current Market Cap: $10.69B
For detailed information about QGEN stock, go to TipRanks’ Stock Analysis page.